<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2d1 20170631//EN" "JATS-journalpublishing1.dtd">
<article xlink="http://www.w3.org/1999/xlink" dtd-version="1.0" article-type="healthcare" lang="en"><front><journal-meta><journal-id journal-id-type="publisher">IJCRR</journal-id><journal-id journal-id-type="nlm-ta">I Journ Cur Res Re</journal-id><journal-title-group><journal-title>International Journal of Current Research and Review</journal-title><abbrev-journal-title abbrev-type="pubmed">I Journ Cur Res Re</abbrev-journal-title></journal-title-group><issn pub-type="ppub">2231-2196</issn><issn pub-type="opub">0975-5241</issn><publisher><publisher-name>Radiance Research Academy</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">4151</article-id><article-id pub-id-type="doi"/><article-id pub-id-type="doi-url">http://dx.doi.org/10.31782/IJCRR.2021.131911</article-id><article-categories><subj-group subj-group-type="heading"><subject>Healthcare</subject></subj-group></article-categories><title-group><article-title>Development and Validation of Reverse Phase Chiral HPLC Method for Quantification of Enantiomer in Lamivudine Drug Substance&#13;
</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>N</surname><given-names>Siva Jyothi</given-names></name></contrib><contrib contrib-type="author"><name><surname>M</surname><given-names>Venkatnarayana</given-names></name></contrib></contrib-group><pub-date pub-type="ppub"><day>11</day><month>10</month><year>2021</year></pub-date><volume>9)</volume><issue/><fpage>137</fpage><lpage>141</lpage><permissions><copyright-statement>This article is copyright of Popeye Publishing, 2009</copyright-statement><copyright-year>2009</copyright-year><license license-type="open-access" href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution (CC BY 4.0) Licence. You may share and adapt the material, but must give appropriate credit to the source, provide a link to the licence, and indicate if changes were made.</license-p></license></permissions><abstract><p>Introduction: Chiral HPLC is a chromatographic separation technique used to separate the Enantiomer or Diastereomer from the main active compound. Aim: A simple, rapid and robust reverse phase chiral HPLC method was developed and validated for the quantification of Lamivudine Enantiomer in Lamivudine drug substance. Methodology: The Enantiomer of Lamivudine was resolved in Lux cellulose-5 column using a mobile phase containing Methanol: Diethylamine (100:0.1 v/v) at a flow rate of 0.5 mL/min. Results: The resolution between Enantiomer and Lamivudine was found to be more than 1.5 in an optimized method. The developed method was validated and proved that the method was specific, sensitive, accurate and precise as per ICH. The limit of detection and limit of quantification for Lamivudine Enantiomer was 0.004% and 0.012% respectively. The linearity curve was found to be linear and the correlation coefficient obtained was 0.999. The average percentage recoveries of Enantiomer were in the range of 97 to 102%. Conclusion: The proposed method was found to be suitable and accurate for the quantitative determination of Enantiomer in Lamivudine drug substance.&#13;
</p></abstract><kwd-group><kwd>Enantiomer</kwd><kwd> Lamivudine</kwd><kwd> Reverse phase chiral HPLC</kwd><kwd> Lux cellulose-5 column</kwd><kwd> Sensitivity</kwd><kwd> Method development</kwd><kwd> Method  validation</kwd><kwd> ICH guidelines</kwd></kwd-group></article-meta></front></article>
